drugset
drugset / Trial / NCT06911333

AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

NCT06911333 ↗

Phase 1/2 Recruiting 36 enrolled Avelos Therapeutics Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or metastatic solid tumors. The main questions it aims to answer are: * Which dosage of AD1208 is safe and tolerable for participants? * What medical problems do participants have when taking AD1208? Participants will: * Take drug AD1208 every day up to 1 cycle at the least. * Visit the site once every 1 weeks for checkups and tests during cycle 1 and every 3 weeks from cycle 2 onwards. * Keep a diary of any adverse events and administrated drug

Timeline

Start
2025-03-11
Primary completion
2029-06-30
Completion
2030-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject AD1208 Unknown 40 mg Oral
Subject AD1208 Unknown 80 mg Oral
Subject AD1208 Unknown 140 mg Oral
Subject AD1208 Unknown 240 mg Oral
Subject AD1208 Unknown 340 mg Oral

Indications

cancer